Innoviva, Inc.
DE ˙ DB ˙ US45781M1018
19,20 € ↑0,70 (3,78%)
2026-06-04
DEL PRIS
SecurityDE:HVE / Innoviva, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership8,790,044 shares
Ownership 14.00%
BlackRock, Inc. ownership in HVE / Innoviva, Inc.

2025-04-28 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8,790,044 shares of Innoviva, Inc. (DE:HVE). This represents 14.0 percent ownership of the company. In their previous filing dated 2024-01-22 , BlackRock, Inc. had reported owning 10,349,116 shares, indicating a decrease of -15.06 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-04-28 2025-04-28 13G/A 10,349,116 8,790,044 -15.06 14.00 -13.04
2024-01-22 2024-01-22 13G/A 10,611,839 10,349,116 -2.48 16.10 5.92
2023-02-10 2023-02-10 13G/A 5,671,100 10,611,839 87.12 15.20 43.40
2023-01-26 2023-01-26 13G/A 5,671,100 5,671,100 0.00 10.60 0.00
2023-01-20 2023-01-20 13G 9,008,758 5,671,100 -37.05 10.60 -18.46
2022-01-28 2022-01-28 13G/A 11,160,546 9,008,758 -19.28 13.00 18.18
2021-01-27 2021-01-27 13G/A 11,160,546 11,160,546 0.00 11.00 0.00
2021-01-27 2021-01-27 13G/A 11,498,046 11,160,546 -2.94 11.00 -3.51
2020-02-04 2020-02-04 13G/A 11,792,976 11,498,046 -2.50 11.40 -2.56
2019-01-28 2019-01-28 13G/A 11,291,145 11,792,976 4.44 11.70 11.43
2018-02-08 2018-02-08 13G/A 11,397,869 11,291,145 -0.94 10.50 0.00
2017-01-12 2017-01-12 13G/A 11,554,129 11,397,869 -1.35 10.50 -0.94
2017-01-12 2017-01-12 13G/A 11,554,129 11,397,869 -1.35 10.50 -0.94
2016-12-09 2016-12-09 13G/A 7,038,451 11,554,129 64.16 10.60 76.67
2016-12-09 2016-12-09 13G/A 7,038,451 11,554,129 64.16 10.60 76.67
2016-02-10 2016-02-10 13G/A 7,038,451 6.00
2015-02-02 2015-02-02 13G 6,815,020 5.90
2012-09-10 2012-09-10 13G/A 4,694,933 4.85
2012-02-08 2012-02-08 13G/A 4,943,336 5.77

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F INNOVIVA COM 45781M101 11,307,845 631,070 5.91 263,473 23.45 0.0046
2026-02-12 2025-12-31 13F INNOVIVA COM 45781M101 10,676,775 1,239,963 13.14 213,429 23.93 0.0036
2025-11-12 2025-09-30 13F INNOVIVA COM 45781M101 9,436,812 320,395 3.51 172,222 -5.97 0.0030
2025-08-12 2025-06-30 13F INNOVIVA COM 45781M101 9,116,417 -98,266 -1.07 183,149 9.63 0.0035
2025-05-02 2025-03-31 13F INNOVIVA COM 45781M101 9,214,683 -309,567 -3.25 167,062 1.10 0.0035
2025-02-07 2024-12-31 13F INNOVIVA COM 45781M101 9,524,250 99,401 1.05 165,246 -9.20 0.0033
2024-11-13 2024-09-30 13F INNOVIVA COM 45781M101 9,424,849 -204,510 -2.12 181,994 15.24 0.0038
2024-08-13 2024-06-30 13F INNOVIVA COM 45781M101 9,629,359 -512,781 -5.06 157,921 2.17 0.0036
2024-05-10 2024-03-31 13F INNOVIVA COM 45781M101 10,142,140 8,716,906 611.61 154,566 2,577.86 0.0036
2024-02-13 2023-12-31 13F THESEUS PHARMACEUTICALS COM 88369M101 1,425,234 84,754 6.32 5,772 60.11 0.0001
2024-02-13 2023-12-31 13F INNOVIVA COM 45781M101 10,352,073 908,301 166,047 0.0042
2023-11-13 2023-09-30 13F THESEUS PHARMACEUTICALS COM 88369M101 1,340,480 6,612 0.50 3,606 -71.03 0.0001
2023-11-13 2023-09-30 13F INNOVIVA COM 45781M101 9,443,772 -255,987 122,675 0.0035
2023-08-11 2023-06-30 13F THESEUS PHARMACEUTICALS COM 88369M101 1,333,868 450,406 50.98 12,445 58.62 0.0003
2023-08-11 2023-06-30 13F INNOVIVA COM 45781M101 9,699,759 -640,932 123,478 0.0034
2023-05-12 2023-03-31 13F THESEUS PHARMACEUTICALS COM 88369M101 883,462 18,405 2.13 7,845 82.15 0.0002
2023-05-12 2023-03-31 13F INNOVIVA COM 45781M101 10,340,691 -183,515 116,333 0.0034
2023-02-13 2022-12-31 13F THESEUS PHARMACEUTICALS COM 88369M101 865,057 89,467 11.54 4,308 -4.27 0.0001
2023-02-13 2022-12-31 13F INNOVIVA COM 45781M101 10,524,206 338,658 139,446 0.0044
2022-11-14 2022-09-30 13F THESEUS PHARMACEUTICALS COM 88369M101 775,590 88,231 12.84 4,499 18.36 0.0002
2022-11-14 2022-09-30 13F INNOVIVA COM 45781M101 10,185,548 92,620 118,253 0.0040
2022-08-12 2022-06-30 13F THESEUS PHARMACEUTICALS COM 88369M101 687,359 142,504 26.15 3,801 -39.49 0.0001
2022-08-12 2022-06-30 13F INNOVIVA COM 45781M101 10,092,928 1,108,125 148,973 0.0048
2022-05-12 2022-03-31 13F THESEUS PHARMACEUTICALS COM 88369M101 544,855 11,592 2.17 6,282 -7.08 0.0002
2022-05-12 2022-03-31 13F INNOVIVA COM 45781M101 8,984,803 -23,955 173,855 0.0047
2022-02-10 2021-12-31 13F THESEUS PHARMACEUTICALS COM 88369M101 533,263 -8,311,463 -93.97 6,761 -95.43 0.0002
2022-02-10 2021-12-31 13F INNOVIVA COM 45781M101 9,008,758 164,032 155,399 0.0040
2021-11-09 2021-09-30 13F INNOVIVA COM 45781M101 8,844,726 -1,234,901 -12.25 147,794 9.34 0.0041
2021-08-11 2021-06-30 13F INNOVIVA COM 45781M101 10,079,627 -1,269,789 -11.19 135,169 -0.34 0.0038
2021-05-07 2021-03-31 13F INNOVIVA COM 45781M101 11,349,416 188,870 1.69 135,626 -1.92 0.0040
2021-02-05 2020-12-31 13F INNOVIVA COM 45781M101 11,160,546 136,096 1.23 138,279 20.03 0.0044
2020-11-06 2020-09-30 13F INNOVIVA COM 45781M101 11,024,450 -632,187 -5.42 115,204 -29.31 0.0043
2020-08-14 2020-06-30 13F INNOVIVA COM 45781M101 11,656,637 463,698 4.14 162,960 23.80 0.0065
2020-05-01 2020-03-31 13F INNOVIVA COM 45781M101 11,192,939 -305,107 -2.65 131,630 -19.15 0.0064
2020-02-13 2019-12-31 13F INNOVIVA COM 45781M101 11,498,046 268,027 2.39 162,812 37.55 0.0062
2019-11-08 2019-09-30 13F INNOVIVA COM 45781M101 11,230,019 -354,287 -3.06 118,363 -29.82 0.0050
2019-08-22 2019-06-30 13F/A-1 INNOVIVA COM 45781M101 11,584,306 -165,134 -1.41 168,668 2.32 0.0072
2019-08-13 2019-06-30 13F INNOVIVA COM 45781M101 11,584,306 -165,134 168,668
2019-05-09 2019-03-31 13F INNOVIVA COM 45781M101 11,749,440 -43,536 -0.37 164,846 -19.90 0.0074
2019-02-08 2018-12-31 13F INNOVIVA COM 45781M101 11,792,976 -128,622 -1.08 205,788 13.27 0.0104
2018-11-09 2018-09-30 13F INNOVIVA COM 45781M101 11,921,598 304,918 2.62 181,684 13.33 0.0079
2018-08-09 2018-06-30 13F INNOVIVA COM 45781M101 11,616,680 744,273 6.85 160,311 -11.55 0.0074
2018-05-09 2018-03-31 13F INNOVIVA COM 45781M101 10,872,407 -418,536 -3.71 181,243 13.12 0.0087
2018-02-09 2017-12-31 13F INNOVIVA COM 45781M101 11,290,943 -157,497 -1.38 160,218 -0.89 0.0076
2017-11-14 2017-09-30 13F INNOVIVA COM 45781M101 11,448,440 -518,730 -4.33 161,653 5.53 0.0082
2017-08-10 2017-06-30 13F INNOVIVA COM 45781M101 11,967,170 -33,089 -0.28 153,178 -7.70 0.0081
2017-05-12 2017-03-31 13F INNOVIVA COM 45781M101 12,000,259 11,982,693 68,215.26 165,964 88,650.80 0.0091
2017-02-10 2016-12-31 13F INNOVIVA COM 45781M101 17,566 -8,862 -33.53 187 -35.74 0.0003
2016-11-08 2016-09-30 13F INNOVIVA COM 45781M101 26,428 529 2.04 291 6.59 0.0004
2016-08-10 2016-06-30 13F INNOVIVA COM 45781M101 25,899 19,827 326.53 273 259.21 0.0004
2016-05-10 2016-03-31 13F INNOVIVA COM 45781M101 6,072 3,206 111.86 76 153.33 0.0001
2016-02-11 2015-12-31 13F THERAVANCE COM 88338T104 2,866 620 27.60 30 76.47 0.0000
2015-11-13 2015-09-30 13F THERAVANCE COM 88338T104 2,246 0 0.00 17 -57.50 0.0000
2015-08-07 2015-06-30 13F THERAVANCE COM 88338T104 2,246 -114 -4.83 40 8.11 0.0001
2015-05-13 2015-03-31 13F THERAVANCE COM 88338T104 2,360 0 0.00 37 12.12 0.0001
2015-02-09 2014-12-31 13F THERAVANCE COM 88338T104 2,360 0 0.00 33 -19.51 0.0000
2014-10-29 2014-09-30 13F THERAVANCE COM 88338T104 2,360 0 0.00 41 -41.43 0.0001
2014-08-06 2014-06-30 13F THERAVANCE COM 88338T104 2,360 -1,968 -45.47 70 -47.76 0.0001
2014-05-02 2014-03-31 13F THERAVANCE COM 88338T104 4,328 -487 -10.11 134 -22.09 0.0002
2014-02-12 2013-12-31 13F THERAVANCE COM 88338T104 4,815 179 3.86 172 -9.47 0.0003
2013-11-12 2013-09-30 13F THERAVANCE COM 88338T104 4,636 41 0.89 190 7.34 0.0004
2013-08-13 2013-06-30 13F THERAVANCE COM 88338T104 4,595 4,595 177 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.